Drug
Pegcetacoplan
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Vitreous Floaters | 112 | 137.1 | 146.3 | signal |
| 2 | Eye Inflammation | 66 | 83.0 | 86.2 | signal |
| 3 | Uveitis | 78 | 68.5 | 71.5 | signal |
| 4 | Intraocular Pressure Increased | 53 | 48.8 | 50.3 | signal |
| 5 | Blood Lactate Dehydrogenase Increased | 42 | 31.1 | 31.9 | signal |
| 6 | Infusion Site Pain | 21 | 19.4 | 19.6 | signal |
| 7 | Ocular Discomfort | 16 | 17.4 | 17.5 | signal |
| 8 | Eye Haemorrhage | 19 | 16.8 | 16.9 | signal |
| 9 | Chromaturia | 29 | 15.1 | 15.4 | signal |
| 10 | Haemoglobin Decreased | 124 | 14.2 | 15.2 | signal |
| 11 | Blindness | 47 | 13.6 | 14.0 | signal |
| 12 | Visual Impairment | 137 | 13.1 | 14.2 | signal |
| 13 | Photophobia | 19 | 12.0 | 12.1 | signal |
| 14 | Visual Acuity Reduced | 33 | 11.6 | 11.8 | signal |
| 15 | Cytopenia | 11 | 10.9 | 10.9 | signal |
| 16 | Myelodysplastic Syndrome | 13 | 10.6 | 10.7 | signal |
| 17 | Eye Infection | 10 | 10.5 | 10.6 | signal |
| 18 | Brain Fog | 13 | 10.5 | 10.6 | signal |
| 19 | Retinal Detachment | 8 | 10.3 | 10.3 | signal |
| 20 | Eye Pain | 47 | 10.0 | 10.3 | signal |
| 21 | Incorrect Product Administration Duration | 16 | 9.3 | 9.4 | signal |
| 22 | Blood Urine Present | 15 | 9.3 | 9.4 | signal |
| 23 | Bone Marrow Failure | 16 | 9.2 | 9.3 | signal |
| 24 | Ear Discomfort | 8 | 9.2 | 9.3 | signal |
| 25 | Injection Site Discomfort | 8 | 9.1 | 9.2 | signal |
| 26 | Injection Site Induration | 10 | 9.1 | 9.1 | signal |
| 27 | Bacteraemia | 9 | 9.0 | 9.1 | signal |
| 28 | Ocular Hyperaemia | 33 | 8.3 | 8.5 | signal |
| 29 | Glaucoma | 13 | 8.0 | 8.0 | signal |
| 30 | Macular Degeneration | 8 | 7.9 | 7.9 | signal |
| 31 | Impaired Driving Ability | 7 | 7.3 | 7.3 | signal |
| 32 | Full Blood Count Abnormal | 6 | 6.7 | 6.7 | signal |
| 33 | Blindness Unilateral | 8 | 6.7 | 6.7 | signal |
| 34 | Sars-cov-2 Test Positive | 7 | 6.2 | 6.2 | signal |
| 35 | Thrombotic Microangiopathy | 5 | 6.1 | 6.1 | signal |
| 36 | Viral Infection | 17 | 6.0 | 6.1 | signal |
| 37 | Intentional Dose Omission | 13 | 5.6 | 5.6 | signal |
| 38 | Platelet Count Decreased | 50 | 5.5 | 5.7 | signal |
| 39 | Vision Blurred | 63 | 5.4 | 5.6 | signal |
| 40 | Proteinuria | 8 | 5.0 | 5.0 | signal |
| 41 | Injection Site Swelling | 32 | 5.0 | 5.1 | signal |
| 42 | Injection Site Extravasation | 5 | 4.7 | 4.7 | signal |
| 43 | Dry Eye | 19 | 4.6 | 4.7 | signal |
| 44 | Injection Site Pruritus | 24 | 4.3 | 4.3 | signal |
| 45 | Drug Effect Less Than Expected | 5 | 4.2 | 4.2 | signal |
| 46 | Needle Issue | 10 | 4.1 | 4.1 | signal |
| 47 | Injection Site Discolouration | 4 | 3.8 | 3.8 | signal |
| 48 | Acute Myeloid Leukaemia | 5 | 3.8 | 3.8 | signal |
| 49 | Ovarian Cyst | 3 | 3.5 | 3.5 | no signal |
| 50 | Device Delivery System Issue | 6 | 2.7 | 2.7 | signal |
| 51 | Incorrect Dose Administered By Device | 5 | 2.3 | 2.3 | no signal |
| 52 | Injection Site Pain | 57 | 2.2 | 2.3 | signal |
| 53 | Injection Site Haemorrhage | 14 | 2.1 | 2.1 | signal |
| 54 | Syringe Issue | 3 | 2.0 | 2.0 | no signal |
| 55 | Injection Site Erythema | 21 | 2.0 | 2.0 | signal |
| 56 | Injection Site Mass | 6 | 1.9 | 1.9 | no signal |
| 57 | Device Use Error | 5 | 1.7 | 1.7 | no signal |
| 58 | Device Leakage | 6 | 1.7 | 1.7 | no signal |
| 59 | Gynaecomastia | 4 | 1.5 | 1.5 | no signal |
| 60 | Injection Site Bruising | 10 | 1.5 | 1.5 | no signal |
| 61 | Injection Site Urticaria | 3 | 1.5 | 1.5 | no signal |
| 62 | Wrong Technique In Device Usage Process | 3 | 0.8 | 0.8 | no signal |